Research Analysts Offer Predictions for AUTL Q1 Earnings

Autolus Therapeutics plc (NASDAQ:AUTL) – Stock analysts at William Blair issued their Q1 2026 earnings estimates for Autolus Therapeutics in a research report issued on Wednesday, April 23rd. William Blair analyst M. Phipps forecasts that the company will post earnings per share of ($0.27) for the quarter. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share. William Blair also issued estimates for Autolus Therapeutics’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.18) EPS.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $2.98 million.

Several other research firms also recently commented on AUTL. Needham & Company LLC restated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Thursday, April 10th. Wells Fargo & Company reduced their price target on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 21st. Finally, Truist Financial lowered their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $9.32.

Autolus Therapeutics Trading Down 5.0 %

AUTL stock opened at $1.33 on Friday. The business’s fifty day moving average price is $1.63 and its 200 day moving average price is $2.46. Autolus Therapeutics has a 12-month low of $1.11 and a 12-month high of $5.00. The company has a market capitalization of $353.91 million, a PE ratio of -1.10 and a beta of 2.06.

Institutional Trading of Autolus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AUTL. Hennion & Walsh Asset Management Inc. purchased a new position in Autolus Therapeutics during the fourth quarter worth about $611,000. JPMorgan Chase & Co. raised its stake in shares of Autolus Therapeutics by 145.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock worth $4,663,000 after buying an additional 761,008 shares in the last quarter. State Street Corp lifted its holdings in shares of Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after buying an additional 10,401 shares during the period. Handelsbanken Fonder AB lifted its holdings in shares of Autolus Therapeutics by 30.9% in the 4th quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company’s stock valued at $172,000 after buying an additional 17,300 shares during the period. Finally, Wellington Management Group LLP boosted its stake in shares of Autolus Therapeutics by 4.6% in the fourth quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock valued at $59,562,000 after buying an additional 1,125,454 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.